Paracrine signaling network of Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC secretome)

The paracrine signaling network of Bone Marrow-derived Mesenchymal Stem Cells (BM-MSCs) is the primary mechanism by which these cells exert therapeutic effects, involving the secretion of a diverse array of bioactive molecules known as the secretome (PMID: 30631533). This network includes growth factors such as VEGF and HGF, cytokines like IL-10 and TGF-beta, and extracellular vesicles that collectively modulate the local microenvironment to promote tissue regeneration and suppress inflammation (PMID: 31131320). BM-MSCs respond to inflammatory signals like IFN-gamma and TNF-alpha by releasing immunomodulatory factors such as Indoleamine 2,3-dioxygenase (IDO) and Prostaglandin E2 (PGE2), which inhibit T-cell proliferation and promote M2 macrophage polarization (Nature Reviews Rheumatology, 2015). In clinical contexts, this network is leveraged for treating conditions like graft-versus-host disease and myocardial infarction, where the goal is to harness the cells' innate ability to coordinate complex repair processes. However, because it is a multi-component system rather than a single molecular target, it presents significant challenges for pharmacological standardization and regulatory approval (PMID: 28619192).

Other names

Bone marrow mesenchymal stem cell secretomeBM-MSC paracrine factorsMSC-derived secretomeMesenchymal stem cell-conditioned medium

The network functions through the secretion of bioactive molecules that modulate the local microenvironment, suppressing inflammatory immune responses and promoting endogenous tissue regeneration and vascularization.